Search Bar & Filters
Found 27 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating patient characteristics, treatment patterns, and both short- and long-term outcomes in people with symptomatic obstructive hypertrophic cardiomyopathy HCM in the United States and Europe. The study focuses on patients receiving mavacamten, other treatments, or no treatment due to intolerance or previous treatment failure. The US sub-study particularly assesses mavacamtens safety, while the European sub-study evaluates both the safety and effectiveness of mavacamten in real-world settings. Participants receive treatment as prescribed by their physicians according to standard care for symptomatic obstructive HCM. One group takes mavacamten, while another receives beta-blockers, non-dihydropyridine calcium channel blockers, andor disopyramide. Some participants may be untreated due to intolerance or treatment failure. Treatments follow routine clinical care without study-driven changes. Throughout the study, participants are monitored for heart function changes, including heart failure events and left ventricular outflow tract gradients, over periods up to five years. Researchers collect data on arrhythmias, hospitalizations, mortality, and quality of life using questionnaires and biomarker tests. This observational registry captures real-world experiences to better understand treatment outcomes and patient health over time.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.
Actively Recruiting
Researchers are collecting clinical data on patients who have symptomatic mitral valve disease, including mitral regurgitation, mitral stenosis, or a combination of these conditions. This observational study aims to better understand how fixing symptomatic mitral valve disease affects patient outcomes, especially for those who might be candidates for Transcatheter Mitral Valve Replacement. The findings may also help guide future regulatory decisions and reimbursement strategies for the Cephea Mitral Valve System. Participants include symptomatic patients who may be candidates for transcatheter mitral valve replacement based on assessments by their healthcare team. This registry observes patients who have been treated according to current standards and who are considered better suited for transcatheter therapy than conventional surgery. No specific treatments or interventions are administered by the study instead, data is collected on patients clinical status and care. Participants agree to follow-up data collection over a period extending up to two years after enrollment. The study gathers information on clinical outcomes and health status during this time. No experimental treatments are given as part of the study, but ongoing monitoring and data entry help researchers evaluate the impact of mitral valve disease correction in real-world settings. Total participation duration lasts from enrollment through the two-year follow-up period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the AGENT Drug-Coated Balloon DCB compared to standard percutaneous coronary intervention PCI treatments like drug-eluting stents DES and balloon angioplasty in patients with new de novo coronary artery lesions. This open-label, randomized controlled study includes a pharmacokinetic sub-study and an intravascular ultrasound sub-study to provide additional insights. Participants will be randomly assigned to receive either the AGENT DCB or standard care, which may include drug-eluting stents or balloon angioplasty. The study covers different lesion types such as small vessel, bifurcation with side branches, and long lesions, with treatments tailored accordingly. The procedures are performed as part of PCI, and treatment allocation is done in parallel groups. During the trial, participants will undergo follow-up evaluations to monitor lesion outcomes and safety, including assessments up to 12 months after the procedure. Researchers will measure the rate of target lesion failure at 12 months as the primary outcome. Participants will also be monitored for adherence to protocol and any adverse events, with the overall study lasting until March 2032.
Actively Recruiting
Researchers are studying the safety and effectiveness of a minimally invasive device called the Alleviant ALV1 System in patients with chronic heart failure, specifically those with heart failure with preserved or mildly reduced ejection fraction HFpEFHFmrEF. This prospective, multicenter, randomized, double-blind trial compares the device procedure to a sham control in order to better understand its potential benefits and risks. Participants are randomly assigned to one of two groups. Those in the treatment group undergo cardiac imaging, femoral vein access, and receive the Alleviant ALV1 System device procedure, which creates an interatrial shunt. The control group undergoes cardiac imaging and femoral vein sheath placement without the device procedure. The study has a crossover design, allowing participants to experience both conditions during the trial. During the study, participants will have cardiac imaging and exercise right heart catheterization to monitor heart function and pressures. Researchers will evaluate a composite primary endpoint at 12 months to assess safety and efficacy. Participants will be monitored for ongoing health status while continuing stable guideline-directed medical therapy. The trial is expected to complete by December 2032.
Actively Recruiting
Researchers are conducting an international, multicenter, observational study to assess the performance of the Cordio HearO system in patients with symptomatic chronic heart failure. This non-interventional, prospective, single-arm study aims to collect patient voice recordings to analyze the sensitivity and unique patient noise reduction UPNR capabilities of the HearO device. The study is sponsored by Cordio Medical and focuses on monitoring heart failure events over time. The study consists of two periods a Run-In period where patients submit daily recordings to establish a baseline, followed by a Core period where patients continue daily submissions for up to 24 months or until the study ends. There is no active treatment or intervention beyond data collection using the HearO app, which records patient utterances for later analysis. Participants will submit daily voice recordings throughout the study duration. Researchers will monitor heart failure events, defined as first usable and adjudicated heart failure events, as the primary outcome. The study involves regular data collection without additional interventions, focusing on patient adherence to daily use of the app. The total observation period per participant may last up to 24 months or until a predefined number of heart failure events have occurred.
Actively Recruiting
Researchers are conducting a prospective, international, multicenter registry to collect long-term clinical data on adult patients undergoing percutaneous coronary intervention PCI with drug-coated balloons DCB for new coronary artery disease. The goal is to evaluate outcomes such as safety and effectiveness of DCB in this population. Emory University coordinates the data collection through a centralized database. Participants receive standard medical care without any experimental interventions mandated by the study. The choice of drug-coated balloon, vessel preparation, and additional medications are decided by the treating physician. Data are collected during routine clinical care and entered into a secure database by participating centers. Participants are followed over time with assessments at hospital discharge, 30 days, 6 months, 12 months, and annually up to 5 years after discharge. Researchers monitor key outcomes including target lesion failure, mortality, myocardial infarction, repeat revascularization, vessel failure, thrombosis, and bleeding events. This long-term follow-up provides valuable information about the clinical performance of DCB therapy.
Actively Recruiting
Researchers are evaluating cardiac imaging methods for patients who have undergone left atrial appendage closure LAAC using the Watchman FLX device. The study compares the standard transesophageal echocardiogram TEE, an ultrasound done by placing a probe in the esophagus, with cardiac computerized tomography angiography CTA, a non-invasive imaging technique using x-rays and contrast dye. This study aims to assess device characteristics and potential complications such as leaks and thrombosis after LAAC. Participants will undergo both TEE and cardiac CTA on the same day, 90 days after their LAAC procedure. TEE is performed using a 3D probe to capture detailed images from multiple angles, while cardiac CTA uses advanced CT scanners with ECG gating and contrast to obtain clear images of the heart and device. The study involves only one group of participants who have received the Watchman FLX device. During the study, participants will have routine follow-up visits according to standard care and a brief phone check-in one year after the procedure. Researchers will measure outcomes such as the percentage of leaks around and inside the device, device-related thrombus, device size, compression, implant depth, and any adverse events. The study lasts one year from the day of the LAAC procedure, with key imaging assessments at three months.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System for patients with severe tricuspid regurgitation who have symptoms and are at an intermediate or higher risk of mortality from tricuspid valve surgery. This randomized, controlled trial compares the device combined with optimal medical therapy OMT to OMT alone. The study is conducted at multiple centers and sponsored by Edwards Lifesciences. Participants are assigned to one of several groups receiving the Edwards PASCAL system plus OMT, OMT alone, or the device with OMT if not eligible for randomization. The transcatheter procedure repairs the tricuspid valve without open surgery. Follow-up visits occur at hospital discharge, 30 days, 3 months, 6 months, and then annually for up to 5 years, allowing long-term monitoring of outcomes. During the study, participants will undergo assessments including quality of life questionnaires, heart imaging, and monitoring for heart failure hospitalizations, mortality, and valve-related events. The main outcome measured at 6 months includes a combination of death, heart device implantation or transplant, valve interventions, hospital admissions for heart failure, and improvement in quality of life. Safety and effectiveness data will be collected throughout the follow-up period of up to 5 years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Shockwave Reducer device for patients with refractory angina pectoris who have persistent chest pain despite maximum medical therapy and are unsuitable for revascularization. This study includes a randomized, double-blind, sham-controlled trial comparing the Shockwave Reducer implant to a placebo procedure, as well as a non-randomized registry for special patient groups such as those with right coronary artery ischemia, abnormal coronary flow reserve, or mobility impairments preventing exercise testing. Participants in the randomized trial are assigned to receive either the Shockwave Reducer implant or a sham procedure with no device implanted. The registry group includes patients treated with the Shockwave Reducer who do not meet randomization criteria. The study involves implantation procedures, with evaluations of heart function and ischemia before enrollment. The trial spans multiple centers and uses a parallel study design. During the study, participants will undergo assessments including exercise tolerance tests, coronary angiography, and imaging to measure ischemia and heart function. Researchers will monitor angina symptoms using the Canadian Cardiovascular Society Angina Score and evaluate safety and effectiveness at six months. Participants are followed up for adherence to therapy and clinical status. The total study duration extends up to the primary completion date in July 2027, with ongoing long-term monitoring until 2032.
1-10 of 27
1